Summit Therapeutics (SMMT) Jefferies London Healthcare Conference 2025 summary

Strategic vision and clinical development

• Focused on advancing ivonescimab, a PD-1/VEGF bispecific antibody, to improve efficacy and safety in cancer treatment.

• Over 40,000 patients have received ivonescimab globally, with 14 phase III trials ongoing, including four global studies and ten in China.

• The molecule is engineered for cooperative binding, offering a shorter half-life and improved tolerability compared to single-agent therapies.

• Clinical data show consistent safety and efficacy across Eastern and Western populations.

Key clinical data and trial updates

• HARMONi-6 phase III trial in China showed a 0.60 hazard ratio for PFS, indicating a 40% improvement over standard care in frontline squamous NSCLC.

• Harmony 3 global trial is over 80% enrolled for the squamous arm, with separate analyses for squamous and non-squamous populations.

• Squamous arm enrollment expected to complete in H1 2026, with data readout in H2 2026; non-squamous arm to complete in H2 2026, with data in H1 2027.

• Both PFS and interim OS analyses are planned for pivotal readouts.

Efficacy, safety, and regulatory progress

• Harmony A trial showed a statistically significant OS benefit (hazard ratio 0.74), with sustained benefit over time and no increase in discontinuations or compounding toxicities.

• Consistent OS and PFS benefits observed across multiple phase III trials, with evidence of an immunotherapy-like long tail effect.

• BLA submission for second-line EGFR-mutant NSCLC planned this quarter, leveraging consistent data across regions and long-term follow-up.

• No other approved therapies in this space have demonstrated an OS benefit.